100 top cell and gene therapy companies to watch in 2023

[Image courtesy of ipopba/Adobe Stock]

The cell and gene therapy sector is poised to deliver a wave of new therapies that could potentially cure rare and common diseases. As many as 13 new cell or gene therapies could be approved for use in the U.S., Europe, or both by the end of 2023.

While manufacturing and regulatory challenges remain, the cell and gene therapy industry continues to offer significant therapeutic potential and commercial opportunities.

This year, we have beefed up our list of leading cell and gene therapy companies, doubling the number of organizations from 50 to 100.

In selecting the companies for this list, we weighed public companies’ degree of involvement in cell and gene therapy, including drug developers, equipment vendors and CDMOs specializing in the area. For private companies, we factored in their funding levels, pipeline and degree of history for the list.

B…

Read more
  • 0

Takeda publishes Phase 3 Livtencity data in peer-reviewed journal

Takeda Pharmaceutical (TSE:4502/NYSE:TAK) has announced that it has published data from the SOLSTICE Phase 3 trial for Livtencity (maribavir) in post-transplant recipients with cytomegalovirus (CMV) infection in the peer-reviewed journal of Clinical Infectious Diseases.

The drug was statistically superior to conventional therapies at week 81. The trial met its primary endpoint. A total of 55.7% (131/235) of adult patients taking Livtencity achieved confirmed CMV DNA level under the lower limit of quantification.

It was also statistically significant to conventional therapies in a composite achievement of CMV DNA level less than the lower limit of quantification (LLOQ). In addition, the drug supported symptom control at week 8 with maintenance through week 161. The conventional therapies in the study included one or more of the antivirals ganciclovir, valganciclovir, foscarnet or cidofovir.

Last month, FDA approved Livtencity for use in patients at least …

Read more
  • 0